Intercontinental Exchange Inc. Common Stock vs Smith & Nephew plc — how do they compare? Intercontinental Exchange Inc. Common Stock trades at $155.43 (market cap $87.21B), while Smith & Nephew plc trades at $27.21 (market cap $11.10B). The key difference: Intercontinental Exchange Inc. Common Stock is far larger — about 7.9× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals.
| ICE | SNN | |
|---|---|---|
Market Cap | $87.21B | $11.10B |
Volume | 2,029,112 | 1,051,703 |
Sector | Financials | Health |
52-Week High | $175.10 | $37.17 |
52-Week Low | $122.91 | $26.42 |
Enterprise Value | $105.12B | $14.13B |
Dividend Yield | 1.34% | 2.95% |
Typical Hold Time | — | 120 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Smith & Nephew (SNN) trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio, though the stock faces headwinds from analyst downgrades and CFO departure news.
The outlook is cautious; while fundamentals show profitability growth, the stock's proximity to lows and mixed analyst sentiment (26% buy, 65% hold) suggest limited near-term upside. Key risks include competitive pressures and execution challenges, but the stable dividend and institutional interest offer some support for patient investors.
Trailing returns across standard periods
Latest headlines on both assets
Intercontinental Exchange provides technology and data services for financial institutions, corporations, and governments. Its businesses include exchanges and clearing, fixed-income data and analytics, and mortgage technology.
Read more on ICE →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →